Robert Kay - Ibio Executive Chairman and CEO
| IBIO Stock | USD 1.76 0.04 2.33% |
Chairman
Mr. Robert B. Kay is the Executive Chairman of the Board, Chief Executive Officer of iBio, Inc., since 2008. Mr. Kay was a founder and senior partner of the New York law firm of Kay Collyer Boose LLP, with a particular focus on mergers and acquisitions and joint ventures. Mr. Kay received his B.A. from Cornell Universitys College of Arts Sciences and his J.D. from New York University Law School since 2008.
| Age | 84 |
| Tenure | 16 years |
| Address | 8800 Health Science Center Parkway, Bryan, TX, United States, 77807-1107 |
| Phone | 302 355 0650 |
| Web | https://www.ibioinc.com |
Robert Kay Latest Insider Activity
Tracking and analyzing the buying and selling activities of Robert Kay against Ibio stock is an integral part of due diligence when investing in Ibio. Robert Kay insider activity provides valuable insight into whether Ibio is net buyers or sellers over its current business cycle. Note, Ibio insiders must abide by specific rules, including filing SEC forms every time they buy or sell Ibio'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Robert Kay over two weeks ago Disposition of 6666 shares by Robert Kay of Lifetime Brands at 6.09 subject to Rule 16b-3 | ||
Robert Kay over a month ago Disposition of 9440 shares by Robert Kay of Lifetime Brands at 9.76 subject to Rule 16b-3 | ||
Robert Kay over a month ago Disposition of 7641 shares by Robert Kay of Lifetime Brands at 9.76 subject to Rule 16b-3 |
Ibio Management Efficiency
The company has return on total asset (ROA) of (0.302) % which means that it has lost $0.302 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.4827) %, meaning that it created substantial loss on money invested by shareholders. Ibio's management efficiency ratios could be used to measure how well Ibio manages its routine affairs as well as how well it operates its assets and liabilities. As of the 26th of April 2024, Return On Tangible Assets is likely to drop to -0.77. In addition to that, Return On Capital Employed is likely to drop to -1.41. At this time, Ibio's Non Current Assets Total are very stable compared to the past year. As of the 26th of April 2024, Other Current Assets is likely to grow to about 801.8 K, while Total Assets are likely to drop about 39.2 M.Similar Executives
| Found 11 records | CHAIRMAN Age | ||
| Roderick Carter | Acasti Pharma | N/A | |
| Jerrold Grossman | ADMA Biologics | 69 | |
| Russell Plumb | Vaxart Inc | 56 | |
| Jerald Wenker | Acasti Pharma | N/A | |
| George Abercrombie | BioCryst Pharmaceuticals | 63 | |
| David Dodd | GeoVax Labs | 74 | |
| James Bochnowski | Jaguar Animal Health | 74 | |
| Seth Lederman | Tonix Pharmaceuticals Holding | 60 | |
| Ronald Denis | Acasti Pharma | N/A | |
| Steven Elms | ADMA Biologics | 53 | |
| Pankaj Mohan | Sonnet Biotherapeutics Holdings | 59 | |
Management Performance
| Return On Equity | -1.48 | ||||
| Return On Asset | -0.3 |
Ibio Inc Leadership Team
Elected by the shareholders, the Ibio's board of directors comprises two types of representatives: Ibio inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Ibio. The board's role is to monitor Ibio's management team and ensure that shareholders' interests are well served. Ibio's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Ibio's outside directors are responsible for providing unbiased perspectives on the board's policies.
| John McKey, Independent Director | ||
| Mark Giannone, CFO | ||
| Philip Russell, Independent Director | ||
| Glenn Chang, Independent Director | ||
| Lisa Middlebrook, Chief Officer | ||
| Seymour Flug, Director | ||
| Stephen Kilmer, Investor Officer | ||
| Marc JD, General Counsel | ||
| Terence Ryan, Chief Scientific Officer | ||
| Melissa Berquist, VP Health | ||
| James Mullaney, CFO | ||
| Robert Lutz, Chief Officer | ||
| Robert Kay, Executive Chairman and CEO | ||
| Arthur Elliott, Independent Director | ||
| Robert Erwin, President | ||
| Dr DVM, Chief Officer | ||
| Mike Jenkins, VP Operations | ||
| Thomas III, Pres CEO | ||
| Randy Maddux, Strategic Advisor | ||
| Felipe Duran, Chief Officer | ||
| Nick DeLong, VP Devel | ||
| James Hill, Independent Director | ||
| Thomas Isett, Director |
Ibio Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Ibio a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.48 | ||||
| Return On Asset | -0.3 | ||||
| Operating Margin | (414.66) % | ||||
| Current Valuation | 21.11 M | ||||
| Shares Outstanding | 8.61 M | ||||
| Shares Owned By Insiders | 0.17 % | ||||
| Shares Owned By Institutions | 26.90 % | ||||
| Number Of Shares Shorted | 184.45 K | ||||
| Price To Earning | (2.18) X | ||||
| Price To Book | 1.87 X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Ibio in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Ibio's short interest history, or implied volatility extrapolated from Ibio options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Ibio Inc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product. You can also try the Content Syndication module to quickly integrate customizable finance content to your own investment portal.
Complementary Tools for Ibio Stock analysis
When running Ibio's price analysis, check to measure Ibio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ibio is operating at the current time. Most of Ibio's value examination focuses on studying past and present price action to predict the probability of Ibio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ibio's price. Additionally, you may evaluate how the addition of Ibio to your portfolios can decrease your overall portfolio volatility.
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance |
Is Ibio's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ibio. If investors know Ibio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ibio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (15.25) | Revenue Per Share 0.044 | Quarterly Revenue Growth (0.88) | Return On Assets (0.30) | Return On Equity (1.48) |
The market value of Ibio Inc is measured differently than its book value, which is the value of Ibio that is recorded on the company's balance sheet. Investors also form their own opinion of Ibio's value that differs from its market value or its book value, called intrinsic value, which is Ibio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ibio's market value can be influenced by many factors that don't directly affect Ibio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Ibio's value and its price as these two are different measures arrived at by different means. Investors typically determine if Ibio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ibio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.